Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
Sugiyama
Y
Y
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.
Iwatsubo
T
T
Ueda
K
K
Ito
K
K
D015195:Drug Design; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010599:Pharmacokinetics; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment
D004364:Pharmaceutical Preparations